Wechselwirkungen von Cefazolin

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

INVANZ is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. (Fachinformation zu Ertapenem, Gegenanzeigen)

Hypersensitivity Reactions: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. (Fachinformation zu Imipenem und Cilastatin, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Hypersensitivity to cefazolin or other cephalosporin class antibacterial drugs, penicillins, or other beta-lactams (4.1) (Fachinformation zu Cefazolin, Gegenanzeigen)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (Fachinformation zu Cefazolin, Arzneimittelwechselwirkungen)

Co-administration of probenecid with Cefazolin for Injection is not recommended. (Fachinformation zu Cefazolin, Arzneimittelwechselwirkungen)

Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (Fachinformation zu Rifampicin, Warnhinweise)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Use caution when CAYSTON is administered to patients with a known allergic reaction to beta-lactams. (Fachinformation zu Aztreonam, Warnhinweise und Vorsichtsmaßnahmen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Ethacrynic acid may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics. (Fachinformation zu Etacrynsäure, Arzneimittelwechselwirkungen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Cephalosporin Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. (Fachinformation zu Furosemid, Arzneimittelwechselwirkungen)

Increased nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins. (Fachinformation zu Gentamicin, Arzneimittelwechselwirkungen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of antimicrobials Drugs Modulating Glucuronidation Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate… (Fachinformation zu Mycophenolat, Arzneimittelwechselwirkungen)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins (see DOSAGE AND ADMINISTRATION ). (Fachinformation zu Protamin, Vorsichtsmaßnahmen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Those at risk include patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. (Fachinformation zu Aminophyllin, Arzneimittelwechselwirkungen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Before initiating therapy with Meropenem for injection, it is important to inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other β-lactams, and other allergens. (Fachinformation zu Meropenem, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Some drugs (e.g. cefazolin, cephalothin), however, may interfere with certain HPLC techniques. (Fachinformation zu Theophyllin, Arzneimittelwechselwirkungen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (Fachinformation zu Cefazolin, Warnhinweise und Vorsichtsmaßnahmen)